About Endoclear
Endoclear is a company based in San Ramon (United States) founded in 2009 by Brad Vazales was acquired by Avanos in November 2019. Endoclear has raised $8.37 million across 7 funding rounds from investors including Avanos. Endoclear operates in a competitive market with competitors including Belluscura, Lungpacer, hemovent, ALung and OneBreath, among others.
- Headquarter San Ramon, United States
- Founders Brad Vazales
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website endoclearllc.com
- Social LinkedIn X Facebook
- Acquired by Avanos (Nov 2019)
- Legal Name Endoclear Llc
Funding Insights of Endoclear
Endoclear has successfully raised a total of $8.37M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $782.79 thousand completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.37M
- Total Rounds 7
- Last Round Series A — $782,790
- First Round $1.95M
(Feb 2010)
All 7 funding rounds of Endoclear with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | $782,790 | Series A | – | – | – |
| May 2014 | $782,786 | Seed | – | – | – |
| Oct 2011 | $2.4M | Seed | – | – | – |
| Sep 2011 | $500,000 | Seed | – | – | – |
| Aug 2011 | $500,000 | Debt – Conventional | – | – | – |
| Aug 2011 | $1.95M | Seed | – | – | – |
| Feb 2010 | $1.95M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Endoclear
Endoclear has secured backing from 1 investor. Prominent investors backing the company include Avanos.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical devices for pain management and enteral feeding are manufactured. | 2014 | avanos.com | Alpharetta, United States |
Investor details for Endoclear
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Endoclear
1 people are tracked at Endoclear (1 in leadership).
| Name | Role | Group |
|---|---|---|
Brad Vazales | Co-Founder & CEO | Leadership |
Complete people profiles for Endoclear
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Endoclear
4 dated milestones of Endoclear across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Endoclear is founded.
- Funding First funding round of $1.9M.
- Funding Latest funding round, Series A, of $783K.
- Exit Acquired by Avanos.
Competitors of Endoclear
Endoclear operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Belluscura, Lungpacer, hemovent, ALung and OneBreath, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| belluscura.com | 2015 | Dallas, United States | $6.38M | 21 | Provider of medical devices for laparoscopic procedures | |
| lungpacer.com | 2009 | Vancouver, Canada | $121.38M | 62 | Neurostimulation-based pacer for diaphragm strength is developed. | |
| hemovent.com | 2013 | Aachen, Germany | $16.7M | 23 | Equipment for extracorporeal life support and CO2 removal is developed. | |
| alung.com | 1997 | Pittsburgh, United States | $132.56M | 27 | Extracorporeal CO2 removal systems are developed to supplement mechanical ventilation. | |
| onebreathventilators.com | 2013 | Bengaluru, India | $3.45M | 26 | Portable mechanical ventilators for intensive care patients are developed. | |
| briodevice.com | 2010 | Doylestown, United States | $1.94M | – | Medical devices for emergency airway management are developed. | |
| securisyn.com | 2011 | Denver, United States | $16.79M | – | Endotracheal tube stabilization systems for ventilated patients are developed. | |
| breethe.com | 2014 | Montreal, Canada | – | – | Meditation programs are delivered through a mobile app by Breethe. | |
| aircraftmedical.com | 2001 | Edinburgh, United Kingdom | – | 31 | Video laryngoscope with variable length blade |
Detailed competitors of Endoclear
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Endoclear
10 companies that operate in the same segment as Endoclear (Pulmonology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Cancer detection diagnostics assays are developed and offered. | 2005 | Boulder, Colorado, United States | USD 200.16 M | USD 88.5 M | 273 | |
Therapeutic devices for nasal breathing improvement are developed. | 2011 | Sunnyvale, California, United States | USD 176.4 M | – | 66 | |
Non-invasive breath-based diagnostics for cancer and infectious diseases are developed. | 2004 | Cambridge, Cambridgeshire, United Kingdom | USD 166.55 M | – | 202 | |
Protein biologics are developed for treating rare diseases. | 2005 | San Diego, California, United States | USD 171.52 M | USD 190 K | 59 | |
Therapeutics for rare respiratory diseases are developed by Savara Pharma. | 2008 | Austin, Texas, United States | USD 67.82 M | – | 59 | |
Developer of smart devices for treating pulmonary diseases | 1998 | Redwood City, California, United States | USD 280.91 M | USD 90.5 M | 291 | |
A norovirus vaccine is developed for infection prevention. | 2021 | Boston, Massachusetts, United States | USD 135 M | – | 14 | |
Oral small molecule drugs for chronic diseases are developed. | 2017 | San Francisco, California, United States | USD 233 M | – | 163 | |
Precision medicines for lung-related diseases are developed. | 2015 | Menlo Park, California, United States | USD 371 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Endoclear
Endoclear was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Endoclear is headquartered in San Ramon, United States. It is registered at San Ramon, California, United States.
Brad Vazales is the current CEO of Endoclear. They have also founded this company.
Endoclear is a funded company, having raised a total of $8.37M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.95M, raised on Feb 2010.
Endoclear develops devices to clear away film and blockages in breathing tubes. The company has developed endOclear, a device that removes mucus and secretions, biofilm, and bacteria from ventilated patients endotracheal tubes and is meant for patients who need a ventilator for more than 48 hours. It combines a clearing technology that physically removes mucus, secretions, and biofilm from the walls of endotracheal tubes in a closed system with suction.
Endoclear's top competitors include Belluscura, Lungpacer and hemovent.
Endoclear has 1 investor. Key investors include Avanos.
Endoclear operates through Endoclear Llc.
Yes. Endoclear was acquired by Avanos in November 2019.